Hemagen completes purchase of Cellular Products:
This article was originally published in Clinica
Hemagen Diagnostics has completed the acquisition of Cellular Products. The purchase is intended to add capacity to Hemagen's production diagnostic kits. Cellular Products has been operating under Chapter 11 bankruptcy protection since 1994, but has been profitable for the two most recent quarters with annual revenues running at around $1.9 million.